SAGE Therapeutics Inc. (SAGE)

140.79
NASDAQ : Health Technology
Prev Close 144.05
Day Low/High 138.90 / 144.40
52 Wk Low/High 79.88 / 193.56
Avg Volume 374.20K
Exchange NASDAQ
Shares Outstanding 51.82M
Market Cap 7.33B
EPS -8.10
P/E Ratio N/A
Div & Yield N.A. (N.A)
SAGE Therapeutics Reports Third Quarter 2014 Results

SAGE Therapeutics Reports Third Quarter 2014 Results

SAGE-547 Phase 1/2 Study Meets Primary Efficacy and Safety Endpoints

Severe Epileptic Patients in Coma Respond to Sage Therapeutics Experimental Drug

Severe Epileptic Patients in Coma Respond to Sage Therapeutics Experimental Drug

Based on promising results from a small study, Sage expects to start a larger phase III study of its anti-seizure drug next year.

First Evaluation Of SAGE-547 To Treat Super-Refractory Status Epilepticus In Children Published In Annals Of Neurology

First Evaluation Of SAGE-547 To Treat Super-Refractory Status Epilepticus In Children Published In Annals Of Neurology

Use of SAGE-547 Resolved Status Epilepticus With No Serious Adverse Events

SAGE Therapeutics Initiates Exploratory Study Of SAGE-547 In Essential Tremor

SAGE Therapeutics Initiates Exploratory Study Of SAGE-547 In Essential Tremor

Study to Further Evaluate SAGE-547 Mechanism of Action

SAGE Therapeutics Appoints Michael F. Cola To The Company's Board Of Directors

SAGE Therapeutics Appoints Michael F. Cola To The Company's Board Of Directors

Cola Brings Industry and Leadership Expertise to SAGE's Advancing Clinical Assets

SAGE Therapeutics Presents New Preclinical Data On SAGE-217 At Eilat Conference On New Anti-Epileptic Drugs

SAGE Therapeutics Presents New Preclinical Data On SAGE-217 At Eilat Conference On New Anti-Epileptic Drugs

SAGE Therapeutics (NASDAQ: SAGE) today presented preclinical data on its second-generation neuroactive steroid, SAGE-217, at the Twelfth Eilat Conference on New Anti-Epileptic Drugs in Madrid, Spain.

SAGE Therapeutics Reports Second Quarter 2014 Financial Results

SAGE Therapeutics Reports Second Quarter 2014 Financial Results

SAGE Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-threatening, rare central nervous system (CNS) disorders, today provided business updates and...

SAGE Therapeutics To Present At Canaccord Genuity 34th Annual Growth Conference

SAGE Therapeutics To Present At Canaccord Genuity 34th Annual Growth Conference

SAGE Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-threatening, rare central nervous system (CNS) disorders, today announced that Jeffrey Jonas, M.

SAGE Therapeutics Announces Closing Of Initial Public Offering

SAGE Therapeutics Announces Closing Of Initial Public Offering

SAGE Therapeutics, a biopharmaceutical company developing novel medicines to treat life-threatening, rare central nervous system (CNS) disorders, today announced the closing of its initial public offering of 5,750,000...

SAGE Therapeutics Receives Fast Track Designation For Lead Compound SAGE-547 To Treat Status Epilepticus

SAGE Therapeutics Receives Fast Track Designation For Lead Compound SAGE-547 To Treat Status Epilepticus

SAGE Therapeutics (NASDAQ: SAGE), a biopharmaceutical company developing novel medicines to treat life-threatening, rare central nervous system (CNS) disorders, announced today that the U.

SAGE Therapeutics Announces Full Exercise Of Over-Allotment Option

SAGE Therapeutics Announces Full Exercise Of Over-Allotment Option

SAGE Therapeutics (NASDAQ:SAGE), a biopharmaceutical company developing novel medicines to treat life-threatening, rare central nervous system (CNS) disorders, today announced that the underwriters of its initial ...

Sage Therapeutics (SAGE) Stock Soars on First Trading Day After IPO

Sage Therapeutics (SAGE) Stock Soars on First Trading Day After IPO

Sage Therapeutics (SAGE) soared more than 60% on Friday, its first day of trading after the company's IPO.

TheStreet Quant Rating: D (Sell)